Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection

Summary

To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).

Timeline

Start

2019-10-08

Primary completion

2020-04-09

Completion

2020-04-09

Outcome

Met primary endpoint

registry analysis (superiority test); MMH-407 vs Placebo; p = 0.0155; Median Difference (Final Values) -0.89 (95% CI -1.61 to -0.17); ANCOVA NCT04244084 ↗

Drugs

Indications